Combined Effect of Cyclosporine and Sirolimus on Improving the Longevity of Recombinant Adenovirus–Mediated Transgene Expression in the Retina

Wei-Yong Shen, MD; May C. Lai, PhD; John Beilby, MD; Nigel L. Barnett, PhD; Jie Liu, MD; Ian J. Constable, MD; Piroska E. Rakoczy, PhD

Objectives: To reevaluate the longevity and intraocular safety of recombinant adenovirus (rAd)–mediated gene delivery after subretinal injection, and to prolong transgene expression through the combination of 2 synergistic immunosuppressants.

Methods: An rAd vector carrying green fluorescent protein (GFP) gene was delivered subretinally in the rat eye. The GFP expression was monitored in real time by fundus fluorescent photography. Intraocular safety was examined by observation of changes of retinal pigmentation, cell infiltration in virus-contacted area, immunophenotyping for CD4+ and CD8+ cytotoxic T lymphocytes, and CD68+ macrophages, histologic findings, and dark-adapted electroretinography. Two synergistic immunosuppressants, cyclosporine and sirolimus, were used alone or in combination to prolong transgene expression by temporary immunosuppression.

Results: The GFP expression peaked on day 4, dramatically decreased on day 10, and was not detectable on day 14. The decreased GFP expression was coincident with cell infiltration in virus-contacted area. Immunostaining showed that the infiltrating cells were CD4+ and CD8+ cytotoxic T lymphocytes and CD68+ macrophages. Clumped retinal pigmentation and decreased b wave of dark-adapted electroretinogram were observed at 3 to 4 weeks after injection. Histologic examination confirmed rAd-induced retinal degeneration. Transient immunosuppression by cyclosporine and sirolimus, either alone or in combination, improved transgene expression, with the combination being the most efficient. The combined immunosuppression attenuated but did not retard the rAd-induced retinal damage.

Conclusions: Transgene expression mediated by rAd after subretinal delivery is short-term and toxic to the retina. Combination of cyclosporine and sirolimus may act as an immunosuppressive adjunct to prolong rAd-mediated gene transfer.

Clinical Relevance: The intraocular safety of rAd should be carefully considered before clinical trials are performed.


GENE THERAPY, which has the ability to produce high concentrations of therapeutic agents in site for sustained periods, has the potential to change traditional treatments for human diseases. The eye is an ideal target for gene therapy because it is separated from other organs by the blood-retinal barrier, there are a limited number of cells confined to a small space, and transgene expression can be monitored optically without invasive interventions.1-3

Recombinant adenovirus (rAd) is one of the most widely used viral vectors targeting both resting and proliferating cell types. In the eye, subretinal delivery of rAd almost exclusively transduces the retinal pigment epithelium (RPE) with high efficacy.2,4,5 The preferential transduction of RPE cells is potentially useful to develop novel strategies for the treatment of retinal degenerations.6,7 It also seems realistic that delivery of neurotrophic factor genes to the RPE cells could attenuate the progress of retinitis pigmentosa.8,9 However, the longevity of rAd-mediated transgene expression in the eye dramatically varied from days to months in previous studies.2,3,5-7 The use of green fluorescent protein (GFP) as a reporter gene may allow us to noninvasively clarify this issue in living animals.

Host immune responses to E1 and E3 region deleted rAds currently present a general problem for long-term gene delivery. Cytotoxic T lymphocytes have been shown to mediate the destruction of rAd-transduced cells. Humoral response leads to the production of antibodies, inhibiting further delivery of rAd.10,11 Traditionally, the eye has been considered an im-
MATERIALS AND METHODS

GENERATION OF rAd

All manipulations regarding the rAd were performed in accordance with the institutional biosafety guidelines. The GFP was selected as a reporter gene because its expression can be monitored noninvasively in real time in the eye.13 The rAd, Ad.CMV.GFP, has an E1 and partial E3 region deletion, and a titer of $3.0 \times 10^{10}$ plaque-forming units/mL was used in this study.

SUBRETINAL ADMINISTRATION OF Ad.CMV.GFP

All animal experiments adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. Normal congenic pigmented and nonpigmented RCS/rd^y rats 4 to 6 weeks of age were used in this experiment. A 2-µL solution containing $6.0 \times 10^{10}$ plaque-forming units of virus was delivered into the subretinal space as described previously.1,3 Phosphate-buffered saline (PBS) was injected in the same way as a control. Successful administration into the subretinal space was confirmed by the appearance of a subretinal bleb under the operating microscope in nonpigmented eyes and a partial retinal detachment by indirect ophthalmoscopy in pigmented eyes.

IMMUNOSUPPRESSION BY CYCLOSPORINE IN COMBINATION WITH SIROLIMUS

For immunosuppression, cyclosporine (Novartis Pharmaceuticals Australia Pty Limited, North Ryde, Australia) was diluted with water for injection to yield a concentration of 10 mg/mL. Sirolimus (kindly provided by Wyeth-Ayerst Research, Monmouth Junction, NJ) was reconstituted in 0.2% carboxymethylcellulose to a final concentration of 2 mg/mL. The subretinally injected rats were divided into 4 groups: (1) vehicle, 0.2% carboxymethylcellulose (n=9); (2) cyclosporine, 10 mg/kg per day (n=7); (3) sirolimus, 2 mg/kg per day (n=7); and (4) combination of cyclosporine plus sirolimus, 10 and 2 mg/kg per day, respectively (n=11). Immunosuppression was initiated immediately after subretinal administration of Ad.CMV.GFP by intraperitoneal injection once a day for 2 weeks. Carboxymethylcellulose, the vehicle used to reconstitute sirolimus, was injected in the same way as a control. All animals were housed in rooms that were suitable for work with microorganisms and biological hazards under barrier conditions to prevent infection. Animals were weighed weekly for 5 weeks to monitor their general conditions under immunosuppression.

NONINVASIVE EVALUATION OF GFP EXPRESSION AND CLINICAL EXAMINATIONS

The GFP expression was observed by fundus fluorescent photography (FFP) at 4, 7, and 10 days, then weekly for 10 weeks, as reported previously.2,3 The fluorescent signal was assessed by 2 independent observers (W.-Y.S. and M.C.L.) and graded on a scale of 0 to 5 that involved both the transduced area and GFP signal intensity. For area, a score of 5 indicated 80% to 100%; 4, 60% to 79%; 3, 40% to 59%; 2, 20% to 39%; 1, less than 19%; and 0, negative. For intensity, a score of 5 indicated very strong; 4, strong; 3, moderate; 2, weak; 1, very weak; and 0, negative. Fundus color photography was performed periodically in pigmented eyes, and fluorescein angiography was performed when GFP expression was not detectable.

RESULTS

TRANSGENE EXPRESSION AND CHANGES OF RETINAL PIGMENTATION

After subretinal injection of Ad.CMV.GFP, the retina images of nonpigmented eyes appeared to be normal when observed by fundus color photography (Figure 1A). At 4 days after injection, strong GFP expression was detected in all eyes, although there was some variability in the size of the fluorescent area (Figure 1C). However, GFP expression rapidly declined to a basal level at day 10 (Figure 1E) and was not detectable at day 14 by FFP (Figure 1G).

Considering the difficulty of distinguishing penetration-induced retinal damage from rAd-induced toxic effects on histologic examination, fundus color photography was performed in pigmented eyes (n=8) to visualize the changes after rAd administration. The pattern of GFP expression in pigmented eyes was the same as that observed in nonpigmented eyes (Figures 1B, D). However, disturbed pigmentation was observed by 3 to 4 weeks after injection (Figure 1F). Fluorescein angiography further demonstrated an appearance of “RPE window de-
After FFP, 8 eyes were enucleated at days 4, 7, 10, and 14 (2 eyes at each time point) for RPE-choroid-scleral (R-C-S) preparation.22 and 4 eyes were enucleated and snap frozen in optimal cutting temperature compound at day 7 for immunohistochemistry. Four PBS-injected eyes were enucleated at 7 days as controls. The R-C-S whole mounts were examined by fluorescent microscopy to evaluate the association between GFP expression and local cellular infiltration. Frozen sections of 12 to 14 μm thickness were produced for CD4+ and CD8+ cytotoxic T-lymphocyte immunostaining as described previously,22 with the use of monoclonal antibodies against rat CD4+ (1:30), CD8+ (1:50) lymphocytes, and CD68+ (1:300) macrophages (Serotec Inc, Kidlington, Oxford, England).

ELECTRORETINOGRAPHY

Nine eyes received subretinal administration of Ad.CMV.GFP and were treated with vehicle (n=4) or cyclosporine plus sirolimus (n=5), and 6 eyes from age-matched untreated rats were assessed by electroretinography (ERG) at 4 weeks after injection. After anesthesia and pupil dilation, the animals were allowed to adapt to the dark for 30 minutes before the scotopic flash ERGs were performed. A platinum wire loop was placed on each cornea as act as the recording electrode, and a reference electrode was connected to the ear. Ground electrodes were attached to the animal’s back. A xenon strobe light placed 0.5 m in front of the animal presented the flash stimulus at 0.25 Hz. Eight consecutive responses were amplified and averaged by means of a bioamplifier/data recorder (MacLab/2e; ADInstruments).

WHITE BLOOD CELL COUNTING AND SERUM BIOCHEMICAL ANALYSIS

By 5 weeks after injection, blood samples were taken from 20 rats under immunosuppression. From each animal, 0.5 mL of blood was collected in a heparinized tube for analysis of white blood cell count and differential count (Beckman Coulter, Sydney, Australia). Another 2.0 mL of blood was collected for analysis of glucose level and renal and liver function by standard procedures on an automated analyzer (Hitachi 747 Autoanalyzer; Boehringer Mannheim, Sydney, Australia).

HISTOLOGIC EXAMINATION

Eyes were enucleated at 5 (n=22) and 10 (n=14) weeks after injection. After eye enucleation and blood sample collection, the liver and kidney were also harvested. The sampled tissues were fixed by 4% paraformaldehyde for paraffin embedding. Paraffin sections 5 to 6 μm thick were processed for hematoxylin-eosin staining to evaluate the retinal morphologic characteristics, and sections from livers and kidneys were examined for the evidence of systemic toxic effects of immunosuppression.

STATISTICAL ANALYSIS

All results are expressed as mean±SD. Two unpaired groups were compared with the 2-sample t test. Analysis of variance was used to compare 3 or more groups. Differences were considered statistically significant at P<.05.

By fluorescent microscopy of cryosections, cellular infiltration was observed in the subretinal space and neural retina from 7 days after injection (Figure 3A). Immunophenotyping showed that most of the infiltrating cells were CD8+ and CD4+ cytotoxic T lymphocytes (Figure 3B, C), and macrophages (CD68+) were also detected (Figure 3D). By 4 weeks after injection, cell infiltration was dramatically decreased, but retinal degeneration was observed in all rAd-injected eyes, demonstrated as reduced number or total loss of the outer nuclear layer and slightly affected inner nuclear layer (Figure 3E, F). Except for the occasional presence of macrophages (CD68+) at the site of injection, CD4+ and CD8+ cytotoxic T lymphocytes and retinal degeneration were not observed in PBS-injected eyes (data not shown).

PROLONGED TRANSGENE EXPRESSION BY IMMUNOSUPPRESSION

Monitored by real-time observation, the efficiency and longevity of GFP expression in vehicle-treated rats were similar to those observed in nontreated rats. The GFP expression was detected in all groups at 4 days after injection (Figure 4A-C and Figure 5). However, no fluorescent signal was detected in the vehicle-treated group at week
At 4 weeks after injection, the percentage of eyes with GFP expression was 67%, 50%, and 9% in groups treated with cyclosporine plus sirolimus, cyclosporine, and sirolimus, respectively. Single drug application with sirolimus or cyclosporine prolonged GFP expression for up to 4 and 9 weeks, respectively. By 10 weeks after injection, 25% of the eyes in the cyclosporine plus sirolimus–treated group still showed GFP expression (Figure 5).

To compare the effect of different strategies on transgene expression, the levels of GFP expression were graded by semiquantification that involved both the area and intensity of fluorescent signal (Figure 6). Although cyclosporine and sirolimus, either alone or in combination, prolonged GFP expression for up to 4 and 9 weeks, respectively. By 10 weeks after injection, 25% of the eyes in the cyclosporine plus sirolimus–treated group still showed GFP expression (Figure 5).

The combined immunosuppression by cyclosporine plus sirolimus attenuated but did not stop rAd-induced retinal damage (Figure 7). The ERG results are summarized in Table 1. By 4 weeks after injection, the implicit time of the a and b waves and the mean amplitudes of the a wave were not significantly different between groups. However, the mean amplitudes of the b wave significantly decreased in the group treated with the vehicle (0.2% carboxymethylcellulose) ($P<.01$) and slightly decreased in the cyclosporine plus sirolimus–treated groups, respectively ($P<.01$). The GFP expression in cyclosporine plus sirolimus– and cyclosporine-treated groups were comparable for up to 5 weeks. However, from 6 to 9 weeks, the GFP levels in the cyclosporine-treated group were significantly lower than those observed in the cyclosporine plus sirolimus–treated group ($P<.05$). Only the cyclosporine plus sirolimus–treated group demonstrated GFP signal when observed by FFP at 10 weeks after injection.
group, but there was no statistical difference when compared with the normal control group ($P = .29$).

**WHITE BLOOD CELL AND DIFFERENTIAL COUTS AND ANIMAL TOLERANCE TO THE IMMUNOSUPPRESSION**

To monitor the effect of immunosuppression on systemic immunocompetence, peripheral-blood samples were collected for white blood cell count and differential count (Figure 8). Immunosuppression by cyclosporine plus sirolimus significantly decreased the absolute number of white blood cells, in comparison with the vehicle-treated group ($P = .02$). White blood cell differentiation showed that the number of lymphocytes and monocytes was significantly reduced ($P < .001$ and $P = .02$, respectively). Cyclosporine alone significantly reduced lymphocytes and monocytes ($P = .02$ and $P = .03$, respectively) but did not affect the absolute number of total white blood cells ($P = .09$). Sirolimus decreased the number of lymphocytes ($P = .02$) but affected neither the number of monocytes nor the total number of white blood cells ($P = .85$ and $P = .43$, respectively). In all 3 groups, neutrophils were not affected ($P > .30$).
Weight loss occurred in all animals treated with cyclosporine plus sirolimus and cyclosporine, but not by sirolimus or vehicle (Figure 9). Cyclosporine plus sirolimus- and cyclosporine-treated animals continuously experienced weight loss for 1 to 2 weeks but returned to their baseline weight at 1 week after withdrawal of immunosuppression, and all rats with initial weight loss regained weight beyond their pretreatment levels at 2 weeks after the immunosuppression was suspended.

Biochemical analysis showed that all groups had similar blood glucose levels at 5 weeks after injection (Table 2). However, cyclosporine plus sirolimus and cyclosporine significantly increased the levels of urea and creatinine and decreased the levels of inorganic phosphate and alkaline phosphatase, but they did not change the levels of alanine aminotransferase and aspartate aminotransferase. Except for a decreased level of alkaline phosphatase, no other biochemical changes were found in the sirolimus-treated group.

By histologic examination, no pathogenicity was found in the livers and kidneys of all groups that had experienced transient immunosuppression (data not shown).

**COMMENT**

A number of studies have examined rAd-mediated gene transfer after subretinal injection, and the duration of trans-
gene expression varies from 2 weeks to several months. In this study, the length of transgene (GFP) expression was monitored by FFP in real time. We did observe a difference in method sensitivity between FFP in living animals and fluorescent microscopy with R-C-S whole mounts. By fluorescent microscopy, GFP expression was stronger than that observed by FFP, and in some eyes, GFP expression occasionally lasted longer than observed by FFP. In most eyes, however, we detected little GFP expression more than 2 weeks after injection, indicating short-term

**Figure 4.** Fluorescent images showing green fluorescent protein expression in animals treated with transient immunosuppression (A, D, and G were treated with cyclosporine and sirolimus; B, E, and H, with cyclosporine; and C, F, and I, with sirolimus), 4 days (A, B, and C), 4 weeks (F), 5 weeks (D, E, and I), 9 weeks (H), and 10 weeks (G) after injection (original magnification ×6).

**Figure 5.** Percentages of eyes with green fluorescent protein (GFP) expression after recombinant adenovirus injection and immunosuppression. The percentage of positive eyes includes any eye expressing GFP signal detected by fundus fluorescent photography. The data represent 10 to 16 eyes per group from 4 days to 5 weeks, and 4 eyes per group from 6 to 10 weeks after injection. C indicates cyclosporine; S, sirolimus.

**Figure 6.** Grades of green fluorescent protein (GFP) expression in animals treated by different strategies of immunosuppression after subretinal injection of recombinant adenovirus. C indicates cyclosporine; S, sirolimus. Asterisk indicates $P<.01$ vs 2 weeks after injection; dagger, $P<.01$ vs group treated with cyclosporine and sirolimus; and double dagger, $P<.05$ vs group treated with cyclosporine and sirolimus; all by unpaired $t$ test.
rAd-mediated transgene expression. The rAd-induced complications were demonstrated, as cellular infiltration consisted of CD4+ and CD8+ cytotoxic T lymphocytes and CD68+ macrophages, clumped retinal pigmentation, decreased b wave of the ERG, and retinal degeneration on histologic examination. Finally, we have dramatically improved transgene expression through temporary immunosuppression by the combination of 2 synergistic immunosuppressants, cyclosporine and sirolimus.

Traditionally, several sites in the body have been described as having immune privilege, including the eye. Earlier reports suggested that the subretinal space is totally immune-privileged with respect to directly delivered rAd, 12, 23; however, recent investigations showed dramatic controversy. 14, 15 In this study, the gradual decrease of rAd-mediated transgene expression could be the result of several changes, such as the cytomegalovirus promoter shutdown and immune responses to the viral vector and GFP protein. We cannot exclude that the reduction of GFP expression may be partially due to inactivation of the cytomegalovirus promoter. However, we found a coincidence of reduction of GFP expression

Table 1. Dark-Adapted Electroretinography 4 Weeks After Subretinal Injection of Ad.CMV.GFP With or Without Transient (2 Weeks) Immunosuppression

<table>
<thead>
<tr>
<th>Group</th>
<th>No.</th>
<th>a-Wave Implicit Time, ms</th>
<th>a-Wave Amplitude, μV</th>
<th>b-Wave Implicit Time, ms</th>
<th>b-Wave Amplitude, μV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (noninjected control)</td>
<td>6</td>
<td>16.83 ± 0.75</td>
<td>196.50 ± 70.67</td>
<td>83.83 ± 3.06</td>
<td>512.17 ± 98.22</td>
</tr>
<tr>
<td>Ad.CMV.GFP + vehicle</td>
<td>4</td>
<td>16.75 ± 1.28</td>
<td>175.25 ± 37.29</td>
<td>81.00 ± 8.16</td>
<td>378.75 ± 32.04*</td>
</tr>
<tr>
<td>Ad.CMV.GFP + cyclosporine + sirolimus</td>
<td>5</td>
<td>16.20 ± 1.64</td>
<td>184.00 ± 49.89</td>
<td>87.00 ± 9.03</td>
<td>442.80 ± 107.64</td>
</tr>
</tbody>
</table>

*P < .05 vs normal control group by t test.
with recruitment of inflammatory cells. Immunophenotyping showed that most of the infiltrating cells are CD4+ and CD8+ cytotoxic T lymphocytes. We further demonstrated that combined immunosuppression by cyclosporine plus sirolimus extended GFP expression by 6-fold. All of these facts directly and indirectly indicate that the decreased GFP expression with time is more likely due to immune responses. It has been recently demonstrated that subretinal readministration of the recombinant adeno-associated virus still resulted in GFP expression.24 In our own hands, recombinant adeno-associated virus–mediated GFP expression remained relatively consistent for up to 18 months.25 These facts indicate that the rAd-induced immune responses are related to the presence of rAd vector rather than GFP protein. Previous studies have demonstrated that the mechanisms involved in elimination of the rAd vector by host responses include (1) innate immunity, (2) major histocompatibility complex class I–restricted cytotoxic T-cell responses, and (3) types 1 and 2 helper T-cell–mediated cellular and humoral immune responses.26,27 The reason for the lost immune privilege after subretinal delivery of rAd is unclear. It is highly possible that the current technique of subretinal injection breaks the blood-retinal barrier and allows some rAd particles to leak out of the eye. Once the immune system is primed by the leaked rAd, the immune privilege of the eye is lost.14 Moreover, administration of a high dose of adenovirus could also evoke a prominent delayed-type hypersensitivity after the second administration of the same adenoviral vector.28 All these pitfalls limit the application of the first generation of rAd for ocular gene therapy.

It is important to use generally accepted clinical techniques to evaluate the intraocular safety when considering rAd for ocular gene therapy, particularly by subretinal injection. In this study, fundus color photography clearly demonstrated a progressive retinal depigmentation in the rAd-injected area. The results of ERG, used to monitor the retinal function, have been reported previously to be temporarily affected.13 The effect of rAd on ERG response seems to be dependent on the rAd concentration. Delivery of $6 \times 10^7$ plaque-forming units of rAd intravitreally or subretinally resulted in a reversible decrease in ERG.13 In this study, increasing rAd concentration ($6 \times 10^7$ plaque-forming units) induced a significant decrease in the b-wave amplitude of the dark-adapted ERG at 4 weeks after injection. Our results obtained from fundus color photography, ERG, and histologic examination suggest that subretinal delivery of rAd affects the neural retina function, indicating a potential retinal toxic effect.

The mechanism of retinal depigmentation is not clear. There is evidence suggesting that activated peripheral cytotoxic T cells in response to rAd migrate into the injected site, where they induce apoptosis through a Fas-Fas ligand–dependent mechanism.29 Fas receptor has been detected on the RPE cells, and binding of Fas-Fas ligand initiates a cascade of apoptosis.30,31 This theory may also explain our later results showing that the combined immunosuppression improved GFP expression but was unable to stop the progress of retinal damage. Other possible mechanisms by which cytotoxic T cells kill the RPE cells involve perforin-granzyme and tumor necrosis factor interactions.32 It is also possible that the delivered rAd induces proinflammatory cytokine release from RPE or photoreceptors and that they have pathologic effects even before the appearance of inflammatory cells.33 Moreover, the rAd-induced RPE damage can further result in atrophy of the choroidal capillary beds.34 All these alterations will affect transportation of nutrients from the choroid to the neural retina, which further leads to the irreversible retinal degeneration. Once the retina is degenerated, the damage would be permanent.

Several approaches have been taken to circumvent the immune responses to adenoviral vectors, such as deletion of several regions from the adenoviral genome to engineer a less immunogenic vector. Unfortunately, further deletion of the adenoviral genome makes the virus less efficient or more difficult to propagate and obtain in high titer.35,36 The immune responses can be avoided provided that the vectors are delivered into neonatal ani-
mals, which have an immature immune system, but this strategy is not of clinical relevance to ocular gene therapy.

Suppression of the host immune system by immunosuppressants such as cyclosporine, tacrolimus, and everolimus has significantly improved the efficacy of transgene expression. However, most of the currently available immunosuppressants display a narrow range between efficacy and toxic side effects, making them less attractive for clinical application. One strategy to overcome this limitation is to combine low doses of synergistic drugs to achieve more therapeutic effect. In this study, we have demonstrated that transient treatment with cyclosporine and sirolimus significantly prolongs rAd-mediated transgene expression, and the combination is more effective than single-drug application. From the results of white blood cell counting and differential counting, we showed that cyclosporine and sirolimus, either alone or in combination, dramatically decrease the number of lymphocytes and/or monocytes in serum, with the combination being the most effective. These results indicate that transient treatment with cyclosporine and sirolimus resulted in systemically cellular immunosuppression that is sufficient to prolong transgene expression.

Although we could not conclude whether the combined effect is synergistic or additive, a number of previous studies have demonstrated that cyclosporine plus sirolimus acts synergistically on immunosuppression. In the eye, cyclosporine and sirolimus inhibited retinal S-antigen–primed lymphocyte proliferation, and they showed a marked synergistic effect over a wide dose range as determined by a median-effect analysis.

The synergetic effect of cyclosporine and sirolimus calculated in vitro was further confirmed in vivo in the treatment of experimental autoimmune uveoretinitis, demonstrated as complete inhibition of disease in all animals treated with the combination regimen. The synergetic effect of cyclosporine and sirolimus allows the reduced doses of each drug to improve rAd-mediated transgene expression.

Interestingly, we observed rebound GFP expression in the groups treated with cyclosporine plus sirolimus and with cyclosporine but not in the sirolimus-treated group at 1 week after withdrawal of immunosuppression. Peripheral white blood cell counts and differential counts suggest that strong immunosuppression was achieved by cyclosporine plus sirolimus and by cyclosporine. It is possible that the strong effect of cyclosporine plus sirolimus and cyclosporine during the first 2 weeks not only circumvents the systemic immunity but also suppresses cell activity. There is also another possibility, that continuous immunosuppression by cyclosporine plus sirolimus and cyclosporine may inhibit the activity of the cytomegalovirus promoter in certain contents, and withdrawal of immunosuppression could relieve this inhibition.

Finally, some weight loss occurred after the combined immunosuppression, but the weight was quickly regained after withdrawal of the treatment. Although biochemical analysis of serum showed some changes in renal and liver function, histologic examination did not support obvious damage.

Accepted for publication February 1, 2001.

This study was supported by Meditech Research Ltd (Perth, Australia) and the Dora Lush Postgraduate Research Scholarship (Australian National Health and Medical Research Council, Canberra) (Dr Shen).

We thank Frank Shilton for fundus photography and Katrina Spilsbury, PhD, for her valuable comments on the manuscript.

Corresponding author and reprints: Pirosha E. Rakoczy, PhD, Department of Molecular Ophthalmology, Lions Eye Institute, 2 Verdun St, Nedlands, Perth, Western Australia 6009, Australia (e-mail: rakoczy@cyllene.uwa.edu.au).

REFERENCES


8. Cayouette M, Behn D, Sendtner M, Lachapelle P, Gravel C. Intracellular gene trans-
The Journal of the American Medical Association (JAMA) and the Archives of Ophthalmology function as an editorial consortium.

With one submission and one set of reviews, your clinical trial manuscript will be considered for publication in both JAMA and the Archives of Ophthalmology.

Submit your paper to the journal of your choice according to the appropriate “Instructions for Authors” and the following guidelines will apply:

1. If your manuscript is accepted by JAMA, it will be considered for an editorial or commentary in JAMA. Your abstract will also be published in the Archives of Ophthalmology with a commentary or editorial.

2. If your manuscript is accepted by the Archives of Ophthalmology, it will be considered for an editorial or commentary in the Archives of Ophthalmology. Your abstract will also be considered for publication in JAMA and may be accompanied by a commentary or editorial in JAMA.

©2001 American Medical Association. All rights reserved.